Par Drugs And Chemicals Limited has informed the Exchange regarding 'Outcome of the Board Meeting dated 14.05.2026'.
PAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Par Drugs and Chemicals Limited's board meeting on May 14, 2026 approved the audited financial results for Q4 and FY ended March 31, 2026 with an unmodified opinion from statutory auditors Sarupria Somani & Associates. The company paid Rs. 25.14 lakh as bonus (10% of basic salary) to employees in April 2026. The board authorized investments up to Rs. 90 crore in liquid funds, arbitrage funds, and fixed deposits, and renewed banking facilities of Rs. 161 lakh with Kotak Mahindra Bank. A motor vehicle was approved for sale at approximately Rs. 1.50 lakh. However, the auditor's report highlights a critical issue: SEBI has issued an Ex-Parte Interim Order and Confirmatory Order restraining the company's proposed Business Transfer Arrangement (BTA) involving transfer of its primary business to a related party. The company is evaluating legal remedies including challenging the orders before appellate authority.
The financial results show compliance with regulatory requirements, but investors should note that SEBI has blocked a major strategic restructuring of the company's primary business. This regulatory intervention creates significant uncertainty about the company's future operations and business strategy, despite the auditor confirming the going concern basis is appropriate.